

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED APPLICANT ATTORNEY DOCKET NO. FILING DATE APPLICATION NUMBER 08/458,033 06/01/95 HINDLEY 12M2/0930 HOPGOOD CALIMAFDE KALIL ART UNIT PAPER NUMBER & JUDLOWE 60 EAST 42ND STREET NEW YORK NY 10165 DATE MAILED:1 09/30/96 This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS **OFFICE ACTION SUMMARY** C-24x8-9-96 Responsive to communication(s) filed on ____ action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 D.C. 11, 453 Q.G. 213. A shortened statutory period for response to this action is set to expire _______ month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1136(a) 1.136(a). Disposition of Claims ____ is/are pending in the application. Claim(s) Of the above, claim(s) _______ is/are withdrawn from consideration. Claim(s) Claim(s) is/are objected to. Claim(s)_ are subject to restriction or election requirement. Claims **Application Papers** See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. is/are objected to by the Examiner. The drawing(s) filed on _ ____ is __ approved __ disapproved. ☐ The proposed drawing correction, filed on __ tod to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). ☐ All ☐ Some. ☐ None of the CERTIFIED copies of the priority documents have been received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received: ____ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). ttachment(s) Notice of Reference Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). Interview Summary, PTO-413 _iotice of Draftsperson's Patent Drawing Review, PTO-948 Stice of Informal Patent Application, PTO-152 - SEE OFFICE ACTION ON THE FOLLOWING PAGES --

DL-326 (Rev. 10/95)

Serial Number: 08/458,033 -2-

Art Unit: 1201

Claims 1-12 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 5521201. Although the conflicting claims are not identical, they are not patentably distinct from each other because they overlap.

The non-statutory double patenting rejection, whether of the obvious-type or non-obvious-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Van Ornam, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321 (b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78 (d).

Effective January 1, 1994, a registered attorney or agent of record may sign a Terminal Disclaimer. A Terminal Disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 14 and 15 are withdrawn from further consideration by the examiner, 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention, the requirement having been traversed in Paper No. 8.

The following claim corresponding to claim 1 of U.S. Patent No. 5521201 is suggested to applicant under 35 U.S.C. § 135(a) for the purposes of an interference:

--A method of treating impaired glucose tolerance comprising administering to a host suffering therefrom a therapeutically

Art Unit: 1201

effective amount of 5-(4-(2-N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione.

The suggested claim must be copied exactly, although other claims may be proposed under 37 C.F.R. \$1.605(a).

APPLICANT MUST COPY THE PATENT CLAIM WITHIN ONE MONTH FROM THE DATE OF THIS LETTER. THE EXTENSION OF TIME PROVISIONS OF 37 C.F.R. § 1.136(a) DO NOT APPLY TO THIS TIME PERIOD. FAILURE TO COPY THE CLAIM WILL BE TAKEN AS A CONCESSION THAT THE SUBJECT MATTER OF THIS CLAIM IS THE PRIOR INVENTION OF ANOTHER UNDER 35 U.S.C. § 102(g) AND THUS ALSO PRIOR ART UNDER 35 U.S.C. § 103. In re Oguie, 186 USPQ 227 (CCPA 1975).

Applicant need not respond to the remaining issues in this action if a suggested claim is copied for the purpose of an interference within the time limit specified above, 37 C.F.R. § 1.605(b).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Gerstl whose telephone number is (703) 308-4531. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

ROBERT GERSTL FOR A MICENAMINED TO 1900

GERSTL:jd SEPTEMBER 25, 1996 Serial Number: 08/458,033 -2-

Art Unit: 1201

This application contains claims 1-12 are drawn to an invention non-elected with traverse in Paper No. 1. A complete response to the final rejection must include cancellation of non-elected claims or other appropriate action (37 C.F.R. § 1.144) M.P.E.P. § 821.01.

The non-statutory double patenting rejection, whether of the obvious-type or non-obvious-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Van Ornam, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321 (b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78 (d).

Effective January 1, 1994, a registered attorney or agent of record may sign a Terminal Disclaimer. A Terminal Disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 14 and 15 are withdrawn from further consideration by the examiner, 37 C.F.R. \$ 1.142(b), as being drawn to a non-elected invention, the requirement having been traversed in Paper No. 8.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Gerstl whose telephone number is (703) 308-4531. The fax phone number for this Group is (703) 308-4556.

Serial Number: 08/458,033 -3-

Art Unit: 1201

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

GERSTL:jd SEPTEMBER 20, 1996